Inherited genetic susceptibility to multiple myeloma

Morgan, G J; Johnson, D C; Weinhold, N; Goldschmidt, H; Landgren, O; Lynch, H T; Hemminki, K; Houlston, R S
March 2014
Leukemia (08876924);Mar2014, Vol. 28 Issue 3, p518
Academic Journal
Although the familial clustering of multiple myeloma (MM) supports the role of inherited susceptibility, only recently has direct evidence for genetic predisposition been demonstrated. A meta-analysis of two genome-wide association (GWA) studies has identified single-nucleotide polymorphisms (SNPs) localising to a number of genomic regions that are robustly associated with MM risk. In this review, we provide an overview of the evidence supporting a genetic contribution to the predisposition to MM and MGUS (monoclonal gammopathy of unknown significance), and the insight this gives into the biological basis of disease aetiology. We also highlight the promise of future approaches to identify further specific risk factors and their potential clinical utility.


Related Articles

  • Genetics: Profiling a shape-shifter. Humphries, Courtney // Nature;12/15/2011 Supplement, Vol. 480 Issue 7377, pS50 

    The article offers information the findings for the mechanisms of multiple myeloma, which is said to show many forms and symptoms. It says that the disease shows precedence of a monoclonal gammopathy of undetermined significance (MGUS) and shows an increased immunoglobulin production. It says...

  • Continuous therapy with lenalidomide in multiple myeloma.  // British Journal of Hospital Medicine (17508460);Jan2010, Vol. 71 Issue 1, p10 

    The article offers information on the data that evaluates the continuous therapy with Revlimid across all stage of multiple myeloma in the U.S. The data presented during the American Society of Hematology congress demonstrated that lenalidomide has a significant clinical potential in active...

  • Multiple myeloma: Destruction of Ikaros. Seton-Rogers, Sarah // Nature Reviews Cancer;Jan2014, Vol. 14 Issue 1, p9 

    An abstract on the study "Lenalidomide causes selective degradation of IKZF1 and IKZF3 in multiple myeloma cells" by J. Kronke and colleagues is presented.

  • Upper Gastrointestinal Bleeding from Gastric Amyloidosis in a Patient with Smoldering Multiple Myeloma. Gjeorgjievski, Mihajlo; Purohit, Treta; Amin, Mitual B.; Kurtin, Paul J.; Cappell, Mitchell S. // Case Reports in Gastrointestinal Medicine;8/23/2015, Vol. 2015, p1 

    Amyloidosis is a common complication of patients with monoclonal gammopathy of undetermined significance (MGUS), smoldering multiple myeloma (SMM), and multiple myeloma (MM). This proteinaceous material can be deposited intercellularly in any organ system, including the gastrointestinal (GI)...

  • Circulating Regulatory T-Cells in Monoclonal Gammopathies of Uncertain Significance and Multiple Myeloma: In Search of a Role. D’Arena, Giovanni; Rossi, Giovanni; Laurenti, Luca; Statuto, Teodora; D’Auria, Fiorella; Valvano, Luciana; Simeon, Vittorio; Giudice, Aldo; Innocenti, Idanna; De Feo, Vincenzo; Filosa, Rosanna; Musto, Pellegrino; D'Arena, Giovanni; D'Auria, Fiorella // Journal of Immunology Research;7/14/2016, p1 

    The frequency and function of regulatory T-cells (Tregs) in multiple myeloma (MM) are still matter of debate. The percentage and absolute number of circulating Tregs (CD4(+)CD25(+high  density)CD127(-/low  density)) from 39 patients with untreated MM and 44 patients...

  • SNP-based mapping arrays reveal high genomic complexity in monoclonal gammopathies, from MGUS to myeloma status. López-Corral, L; Sarasquete, M E; Beà, S; García-Sanz, R; Mateos, M V; Corchete, L A; Sayagués, J M; García, E M; Bladé, J; Oriol, A; Hernández-García, M T; Giraldo, P; Hernández, J; González, M; Hernández-Rivas, J M; San Miguel, J F; Gutiérrez, N C // Leukemia (08876924);Dec2012, Vol. 26 Issue 12, p2521 

    Genetic events mediating transformation from premalignant monoclonal gammopathies (MG) to multiple myeloma (MM) are unknown. To obtain a comprehensive genomic profile of MG from the early to late stages, we performed high-resolution analysis of purified plasma cells from 20 MGUS, 20 smoldering...

  • Utilization of Magnetic-Activated Cell Sorting and High-Density Single Nucleotide Polymorphism Microarrays Improves Diagnostic Yield and Prognostic Value in Clinical Testing for Patients with Multiple Myeloma and Normal Routine Chromosome Study. Christensen, Todd; Deng, Weiwen; McMahill, Bonnie; Schappert, Joseph; Liu, Weihua; Saleki, Reza; Zou, Ying S. // Acta Haematologica;Aug2014, Vol. 132 Issue 2, p233 

    No abstract available

  • Cancer whacked by souped-up immune cells. Coghlan, Andy // New Scientist;12/15/2012, Vol. 216 Issue 2895, p17 

    The article discusses experiments by researcher Aaron Rapoport and team on the treatment of multiple myeloma cancer with injected immune system T-cells genetically engineered to recognize NY-ESO-1 and LAGE-1 proteins on myeloma cells, noting a 77 percent response rate in the patients.

  • Bortezomib plus Melphalan and Prednisone for Initial Treatment of Multiple Myeloma. San Miguel, Jes�s F.; Schlag, Rudolf; Khuageva, Nuriet K.; Dimopoulos, Meletios A.; Shpilberg, Ofer; Kropff, Martin; Spicka, Ivan; Petrucci, Maria T.; Palumbo, Antonio; Samoilova, Olga S.; Dmoszynska, Anna; Abdulkadyrov, Kudrat M.; Schots, Rik; Jiang, Bin; Mateos, Maria-Victoria; Anderson, Kenneth C.; Esseltine, Dixie L.; Liu, Kevin; Cakana, Andrew; van de Velde, Helgi // New England Journal of Medicine;8/28/2008, Vol. 359 Issue 9, p906 

    Background: The standard treatment for patients with multiple myeloma who are not candidates for high-dose therapy is melphalan and prednisone. This phase 3 study compared the use of melphalan and prednisone with or without bortezomib in previously untreated patients with multiple myeloma who...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics